The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 21, 2014

Filed:

Nov. 24, 2009
Applicants:

Farouc Jaffer, Jamaica Plain, MA (US);

Milind Rajopadhye, Westford, MA (US);

Inventors:

Farouc Jaffer, Jamaica Plain, MA (US);

Milind Rajopadhye, Westford, MA (US);

Assignee:

VisEn Medical, Inc., Waltham, MA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61F 2/82 (2013.01); A61B 5/00 (2006.01); A61B 5/02 (2006.01); A61K 49/00 (2006.01);
U.S. Cl.
CPC ...
A61B 5/02007 (2013.01); A61B 5/0071 (2013.01); A61B 5/0066 (2013.01); A61B 5/0084 (2013.01); A61B 5/0086 (2013.01); A61B 5/0073 (2013.01); A61B 5/0068 (2013.01); A61K 49/0034 (2013.01);
Abstract

The invention provides methods and compositions for determining whether a subject containing a stent immobilized in a blood vessel has asymptomatic stent thrombosis or is at risk of developing clinically symptomatic stent thrombosis. In one approach, the method involves imaging a region of the blood vessel that contains the stent using a probe that contains a fluorochrome, for example, a near-infrared fluorochrome, and a targeting moiety that binds a molecular marker indicative of the presence of asymptomatic stent thrombosis or the development of symptomatic stent thrombosis. To the extent that the subject displays one or more such markers, the probe binds to the markers and increases the local concentration of the probe in the vicinity of the stent. The imaging method identifies those patients that display a higher density of such markers in the vicinity of the stent. As a result, those patients can be monitored for, and/or treated to prevent, symptomatic stent thrombosis.


Find Patent Forward Citations

Loading…